SOLICITATION NOTICE
66 -- Acquisition of an EnSpire Multimode Plate Reader
- Notice Date
- 6/22/2016
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC62600-76
- Archive Date
- 7/2/2016
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, UNITED STATES. Description: The National Cancer Institute (NCI), Center of Cancer Research (CCR), Genetics Branch, plans to procure, on a sole source basis, an EnSpire multimode plate reader system by PerkinElmer, 710 Bridgeport Avenue, Shelton, CT 06484-4794. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System (NAICS) code is 334516 and the business size standard is 1,000 employees. Only one (1) award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance: delivery will be within 90 days from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. Among the defining concepts of the Genetics Branch is one that underlies its basic research focus and others that form the foundation of its clinical and translational research activities. The concept that underlies basic research is that cancer is a genetic disease caused by genetic instability. That instability is a function of all the inherited and acquired effects that mediate plasticity and alterability at the level of DNA. The success of molecular genetics over the past two decades has been the identification of genes involved in pathways of growth and development, and the identification of the mechanisms by which the normal regulation and/or products of these genes are altered in cancer. The elucidation of the necessary and sufficient factors that govern genetic instability, the description of the common and disparate themes among different types of instability, and the cataloging of distinct patterns of gene expression in tumors compared to the normal tissues from which they arise are within the purview and distinct perspective of this branch. There is, in addition, a clinical/translational mantle that this branch is called upon to shoulder. At the clinical level this includes patient cancer risk screening, education, counseling, genetic testing (for those who choose to be tested, with testing provided in a setting that is attentive to all the ethical and legal aspects of the testing decision), and the development of appropriate surveillance and prevention options that take into account the category of risk that an individual patient, family, or population represents. The translational research that supports this clinical enterprise consists of four components: (1) molecular diagnostics; (2) genotype/phenotype correlations; (3) the development of biomarkers that can be used for risk assessment and as intermediate endpoints for chemoprevention trials; and (4) targeted therapy and assays for active agents based on the underlying genetics and mechanism(s) of genetic instability that distinguish a tumor from the normal cells from which it arose. The Genetics Branch also is the site for the intramural NCI initiative to develop a repository and database for high-resolution FISH-mapped STS-tagged BAC clones spaced at 1-2 Mb intervals across the human and murine genomes. We hope that this repository and database will serve as a general resource to the entire biomedical community for exploration of cancer-specific chromosomal aberrations. Technological advances have revolutionized the genome-scale profiling of DNA copy number and sequence, DNA and chromatin modification, and gene expression and have substantially enhanced our understanding of the molecular changes that underlie many cancers. However, functionalizing these findings in a systematic manner remains a challenge. To address this challenge, Dr. Caplen's research is focused on the development and application of technologies that use the manipulation of gene expression to discover the function of a gene in a specific context. Dr. Caplen's Section in the Genetics Branch, NCI uses the perturbations induced by RNA- or DNA-based technologies to interrogate specific aspects of the genetic, transcriptional, and cell-signaling alterations observed in cancer cells. This research will enhance the Genetics Branch's understanding of the mechanistic basis of cancer and will discover new cancer treatment strategies. For this work, it is essential that Dr. Caplen's laboratory be able to conduct state-of-the-art, quantifiable assays, that assess the consequences of manipulating gene expression in cancer cells. This includes the need to measure accurately the amount of nucleic acids, proteins, and metabolites found in cells. The Genetics Branch needs to be able to assess accurately the inhibition of the interaction of nucleic acids and proteins, proteins and proteins, or peptides and proteins, by compounds (e.g. small molecules) and also needs to be able to measure markers of intracellular signaling, enzyme activity, cell structure, cell number, cell proliferation, and cell viability. The overall phenotype of cells also needs to be assessed, along with measurements of the exact location of proteins and other cellular compartments within cells. All of these experiments must be performed under physiologically relevant conditions that will require accurate temperature control and the option for fast read times for some assays (e.g. less than one (1) second per well of a 384 well plate for biochemical assays and under five (5) minutes for imaging assays). 1. The Contractor shall provide the following required specifications: One (1) -EnSight Multimode Plate Reader - Base Unit; Configurable Multimode Plate Reader including standard options: - Filter-based absorbance including 405 nm excitation filter - Desktop computer with 24" monitor - Kaleido data acquisition and analysis software - Temperature control - Shaker with three modes: linear, orbital and double orbital - Positive identification of filters - Plate ID Barcode readers: All four sides of the plate - Plate height sensor - Quad Monochromators - Flourescence intensity top reading module - Scanning of wavelengths detection - Monochromator filters - Flourescence intensity bottom reading - Ultra-sensitive luminescence detection - Imaging extended module - Installation and one-year warranty (parts, labor, and travel) This equipment is manufactured by PerkinElmer. PerkinElmer is the only known manufacturer of a plate reader that specifically is a quad monochromator-based unit with fluorescence intensity top and bottom, absorbance, and temperature control with field upgradeable ultra-sensitive luminescence that meets all of the stated technical and scientific requirements required by the Genetics Branch. PerkinElmer is the only known company capable of providing the required scientific equipment including: a) installation; b) on-site training by the original equipment manufacturer for their equipment, and c) an original equipment manufacturer one (1) year warranty in aggregate. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 1:00PM EDT, on July 1, 2016. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC62600-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC62600-76/listing.html)
- Record
- SN04158465-W 20160624/160622234749-0e0a9f7b510d395958fc77aeeee39730 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |